PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent Application of

: Anticipated Group Art Unit: 1651

Éric DUPONT, et al.

: Examiner: Not Yet Assigned

Conf. No.:

Not Yet Assigned

: Anticipated Class and Subclass:

Appln. No.:

Not Yet Assigned

Class: 424

Subclass: 548

Filed:

Herewith

For:

ANTI-TUMOR THERAPIES COMPRISING: Attorney Docket

A COMBINATION OF A CARTILAGE

: No. **014985-6U1**

EXTRACT AND AN ANTI-NEOPLASTIC : AGENT PROVIDING HIGH EFFICACY :

AND LOW TOXIC SIDE EFFECTS

PRELIMINARY AMENDMENT

Prior to the examination and calculation of fees in the above-identified patent application, please amend the application as follows:

In the claims:

Please cancel claims 1-15, without prejudice.

Please add new claims 16-33 as follows:

16. (New) An anti-tumor composition comprising

an anti-tumor amount of anti-neoplastic agent;

a side effect-reducing amount of a shark cartilage extract; and

a pharmaceutically acceptable carrier.

17. (New) The anti-tumor composition of claim 1, wherein the anti-neoplastic agent is selected from the group consisting of busulfan, thiotepa, chlorambucil, cyclophosphamide, estramustine sodium phosphate, ifosfamide, mechlorethamine hydrochloride, melphalan, carmustine, lomustine, streptozocin, carboplatin, cisplatin, methotrexate sodium, cladribine,

